Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123459
Filing Date
2024-11-07
Accepted
2024-11-07 16:45:24
Documents
86
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rckt-20240930.htm   iXBRL 10-Q 1882698
2 EX-31.1 rckt-ex31_1.htm EX-31.1 16127
3 EX-31.2 rckt-ex31_2.htm EX-31.2 16252
4 EX-32.1 rckt-ex32_1.htm EX-32.1 12311
5 GRAPHIC img173865017_0.jpg GRAPHIC 85148
6 GRAPHIC img173865017_1.jpg GRAPHIC 140884
  Complete submission text file 0000950170-24-123459.txt   9091842

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rckt-20240930.xsd EX-101.SCH 1338760
88 EXTRACTED XBRL INSTANCE DOCUMENT rckt-20240930_htm.xml XML 1530824
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36829 | Film No.: 241436690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)